10268-06-1|2-(2-Chlorophenyl)acetamide| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 10268-06-1 ] Purity: 98% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 10268-06-1 ]

CAS No. :	10268-06-1
Formula :	C₈H₈ClNO
M.W :	169.61
SMILES Code :	O=C(N)CC1=CC=CC=C1Cl
MDL No. :	MFCD00176724
InChI Key :	WBJGNXYBEZIOES-UHFFFAOYSA-N
Pubchem ID :	641141

Safety of [ 10268-06-1 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H319
Precautionary Statements:	P305+P351+P338

Computational Chemistry of [ 10268-06-1 ] Show Less

Physicochemical Properties

Num. heavy atoms	11
Num. arom. heavy atoms	6
Fraction Csp3	0.12
Num. rotatable bonds	2
Num. H-bond acceptors	1.0
Num. H-bond donors	1.0
Molar Refractivity	44.13
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	43.09 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	1.4
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	1.47
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	1.37
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.84
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	1.94
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	1.6

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-2.09
Solubility	1.38 mg/ml ; 0.00814 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-1.98
Solubility	1.77 mg/ml ; 0.0104 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-3.0
Solubility	0.169 mg/ml ; 0.000998 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.29 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.25

Application In Synthesis of [ 10268-06-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 10268-06-1 ]

[ 10268-06-1 ] Synthesis Path-Downstream 1~27

1
[ 10268-06-1 ]
[ 2444-36-2 ]

References: [1]Journal fur praktische Chemie (Leipzig 1954),1900,vol. <2>62,p. 562.
[2]Collection of Czechoslovak Chemical Communications,1964,vol. 29,p. 776 - 794.

2
[ 2856-63-5 ]
[ 10268-06-1 ]

Yield	Reaction Conditions	Operation in experiment
78%	With water; In ethanol; at 50 - 60℃; for 3.5h;	General procedure: Amberlyst A26 OH (0.11 g) was added to a suspension ofthe nitrile (1 mmol) in EtOH?H2O (0.5 mL). The reactionmixture was stirred at 50?60 °C, and the progress of thereaction was followed by TLC. After the completion ofreaction, the mixture was diluted with acetone or EtOAc andfiltered to remove the catalyst. The desired products wereisolated by evaporation of the EtOAc or addition of H2O and filtration of the precipitate.

References: [1]Australian Journal of Chemistry,1988,vol. 41,p. 1717 - 1726.
[2]Synlett,2014,vol. 25,p. 1127 - 1131.
[3]Journal of Organic Chemistry,2012,vol. 77,p. 11399 - 11404.
[4]Journal fur praktische Chemie (Leipzig 1954),1900,vol. <2>62,p. 562.
[5]Collection of Czechoslovak Chemical Communications,1964,vol. 29,p. 776 - 794.
[6]Bulletin de la Societe Chimique de France,1966,p. 1956 - 1966.
[7]Journal of the American Chemical Society,1961,vol. 83,p. 1691 - 1697.
[8]Biocatalysis and Biotransformation,2011,vol. 29,p. 54 - 59.

3
[ 51512-09-5 ]
[ 10268-06-1 ]

References: [1]Journal of the American Chemical Society,1953,vol. 75,p. 4769,4771.
[2]Journal of the American Chemical Society,1984,vol. 106,p. 3344 - 3353.
[3]Archiv der Pharmazie,1988,vol. 321,p. 265 - 272.
[4]ACS Medicinal Chemistry Letters,2017,vol. 8,p. 287 - 292.

4
[ 10268-06-1 ]
[ 6921-34-2 ]
[ 92435-52-4 ]

References: [1]Journal of the American Chemical Society,1953,vol. 75,p. 4769,4771.

5
[ 20026-96-4 ]
[ 10268-06-1 ]
4-(4-Chloro-phenyl)-3-(2-chloro-phenyl)-3H-pyridine-2,6-dione [ No CAS ]

References: [1]Australian Journal of Chemistry,1988,vol. 41,p. 1717 - 1726.

6
[ 10268-06-1 ]
[ 24654-09-9 ]
3,4-Bis-(2-chloro-phenyl)-3H-pyridine-2,6-dione [ No CAS ]

References: [1]Australian Journal of Chemistry,1988,vol. 41,p. 1717 - 1726.

7
[ 10268-06-1 ]
[ 58686-68-3 ]
4-(3-Chloro-phenyl)-3-(2-chloro-phenyl)-3H-pyridine-2,6-dione [ No CAS ]

References: [1]Australian Journal of Chemistry,1988,vol. 41,p. 1717 - 1726.

8
[ 10268-06-1 ]
[ 2216-94-6 ]
3-(2-Chloro-phenyl)-4-phenyl-3H-pyridine-2,6-dione [ No CAS ]

References: [1]Australian Journal of Chemistry,1988,vol. 41,p. 1717 - 1726.

9
[ 553-90-2 ]
[ 10268-06-1 ]
3-(2-chloro-phenyl)-4-hydroxy-pyrrole-2,5-dione [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2001,vol. 11,p. 635 - 639.

10
[ 10268-06-1 ]
[ 626604-78-2 ]
3-{1-[3-(tert-butyl-dimethyl-silanyloxy)-propyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-4-(2-chloro-phenyl)-pyrrole-2,5-dione [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 3245 - 3250.

11
[ 103-81-1 ]
[ 10268-06-1 ]
[ 20101-92-2 ]

References: [1]Organic and Biomolecular Chemistry,2006,vol. 4,p. 2716 - 2723.

12
[ 2444-36-2 ]
[ 10268-06-1 ]

Yield	Reaction Conditions	Operation in experiment
89%		To a solution of 2?chiorophenylacetic acid 129 (2.00 g, 11.80 mmcl,1.00 equiv.) in dry CH,C12 (30.0 mL) was added thionyl chloride (9.80mL, 135.3 irimol, 11.5 equiv.) at 0 °C. The reaction was refiuxed for 2h. The solvent was removed under reduced pressure and the residue was azeotroped with toluene (2 x 5.00 mL) . To a solution of crude acyl chloride in THF (30.0 ml) was added NH3 H20 (60.0 mL), and the reactionwas stirred at room temperature for overnight. The solvent was removed under reduced pressure, and the precipitate was filtered, washed with water, and dried under vacuum to afford the title compound as a white solid (1.77 g, 10.5 mmcl, 89percent yield) . NMR Spectroscopy: 1H NMR (500 MHz, (CD3)2S0, 25 00 6): 7.44 (s, 1H), 7.41?7.38 (m, lH), 7.35?7.33(m, lH) , 7.28?7.24 (m, 2H) , 6.96 (s, lH) , 3.54 (s, 2H) . 13C NMR (125 MHz, (CD3)2S0, 25 00 6): 170.8, 134.3, 133.5, 132.0, 128.8, 128.2,126.9. The ?H NMR data was in good agreement with values reported in the literature (O?Connell, 3. et al. 2006).

References: [1]Patent: WO2018/132636,2018,A1 .Location in patent: Page/Page column 70.
[2]Archiv der Pharmazie,1988,vol. 321,p. 265 - 272.
[3]Journal of the American Chemical Society,1984,vol. 106,p. 3344 - 3353.
[4]ACS Medicinal Chemistry Letters,2017,vol. 8,p. 287 - 292.

13
[ 10268-06-1 ]
[ 71512-21-5 ]